<DOC>
	<DOCNO>NCT01721330</DOCNO>
	<brief_summary>The primary aim study ass whether naltrexone monotherapy effective treating ADHD adult . Medications increase dopamine often effective treatment ADHD . Since naltrexone kappa opioid receptor antagonist , increase dopamine brain . The investigator predict naltrexone monotherapy effective ADHD symptom adult ADHD . The investigator also plan assess effect naltrexone dopamine measure change serum prolactin . The investigator predict naltrexone increase dopamine indexed decrease serum prolactin . This study six-week , double-blind , placebo-controlled pilot study adult 18-55 year age ADHD .</brief_summary>
	<brief_title>A Double-Blind Comparison Naltrexone Placebo Adults With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>This six-week , randomize , double-blind , placebo-controlled , parallel design study adult ADHD naltrexone monotherapy . Eligible consent subject recruit study . The first visit consist meeting study clinician obtain consent , assess eligibility , complete study rating scale . After evaluation , subject complete neuropsychological assessment study rating scale ( two hour ; visit take place multiple day , necessary ) . Subjects randomize naltrexone ( 50 mg ) day breakfast placebo ratio 1:1 increase , tolerate , 100 mg week 1 . Blood drawn prolactin , basic metabolic panel , CBC , LFT 's pre-baseline upon completion study . Ten cc 's ( approximately two teaspoon ) blood require basic metabolic panel , CBC , LFT 's drawing . An additional five cc 's ( approximately one teaspoon ) blood require laboratory test prolactin level draw . Dipstick urine drug test do pre-baseline . Women child bear age also urine pregnancy test pre-baseline . Although every effort make encourage subject keep regularly schedule appointment , event subject unable come office within reasonable timeframe schedule visit , treat research clinician feel subject safety jeopardized , clinician conduct visit subject telephone . However , study evaluation visit ( pre-baseline ) , baseline visit , mid-point visit ( week 3 ) , final study visit may conduct phone . Additionally , phone visit may occur two consecutive visit .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female outpatient 1855 year age . 2 . Diagnosis ADHD , Diagnostic Statistical ManualIV ( DSMIV ) clinical evaluation expert clinician . 3 . A CGI 7 ( among extremely ill patient ) prebaseline visit exclusionary , subject present CGIS 7 point study remove participation . 4 . Subjects present CGIS score 6 ( severely ill ) two consecutive visit week 2 drop study ( i.e . A subject CGI 6 his/her week 3 visit week 4 visit drop study week 4 visit ) . Subjects drop severe worsen symptom exposure study medication receive free follow care describe detailed protocol protocol summary . 5 . Subjects treat anxiety disorder depression stable medication regimen least one month , disorderspecific CGISeverity score â‰¤ 3 ( mildly ill ) score HamiltonDepression HamiltonAnxiety rating scale 15 ( mild range ) . Exclusion Criteria 1 . Any clinically unstable psychiatric condition include history psychosis mania , suicidality , sociopathy , criminality , delinquency . 2 . Current ( last 3 month ) substance use disorder ( alcohol drug ) , 3 . Medical condition treatment either jeopardize subject safety affect scientific merit study include cardiovascular disease , current untreated hypertension , history renal hepatic impairment . 4 . A condition may require treatment opioid analgesic . 5 . Clinically significant abnormal baseline laboratory LFT 's , define LFT 's great ULN . 6 . Mental retardation ( IQ &lt; 80 ) . 7 . Organic brain disorder include delirium , dementia , seizure , stroke , neurosurgery , head trauma loss consciousness . 8 . Pregnant nursing female . 9 . Subjects current adequate treatment ADHD . 10 . Any concomitant medication primarily central nervous system activity specify Concomitant Medication portion protocol ( stable effective treatment regimen SSRI benzodiazepine permit per clinical review ) . 11 . NonEnglish speaking subject allow study follow reason : 1 . The assessment instrument unavailable adequately standardized language ; 2 . Even translation service available , assessment English language conduct Englishspeaking clinician raters Englishspeaking subject already extremely timeconsuming , last many hour , make unfeasible , unrealistic , dubious clinical validity conduct translator nonEnglishspeaking subject ; 3 . Psychiatric questionnaire evaluation tax , add complexity translator potential make patient experience even exhaust .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Psychiatry</keyword>
	<keyword>Non-stimulant treatment</keyword>
</DOC>